In the Real World, People Do Not Stick With GLP-1s for Weight Loss | AMCP Nexus 2024
Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years later according to Prime Therapeutics’ real-world evidence, says Ben Urick, Pharm.D., Ph.D., a health outcomes researcher for the pharmacy benefit manager.
There is almost always a gap between how participants in a clinical trial behave and what happens in the real world.
But that gap is especially wide when it comes to the glucagon-like peptide 1 (GLP-1) drugs such as semaglutide (sold as Wegovy for weight loss) and tirzepatide (sold as Zepbound for weight loss), according to Ben Urick, Pharm.D., Ph.D., a senior principal health outcomes researcher at Prime Therapeutics, a pharmacy benefit management company headquartered in the suburban Twin Cities in Minnesota.
In interview with Managed Healthcare Executive, Urick said Prime’s real-world evidence shows that only 15% of the members who started a GLP-1 for weight loss in 2021 were “persistent” with the drug and still taking it two years later. That low proportion is in sharp contrast with the 85% persistent rate seen in clinical trials, he said.
Urick said clinical trial participants are taking the GLP-1s for sustained weight loss that research is now showing has cardiovascular and other health benefits.
“If you think of how these drugs are actually use in practice, a lot times people are trying to use them to drop, let’s say, 10 to 15 pounds before a wedding or something like that,” Urick said. Once they hit the target, people stop using them, he said.
Addressing the Challenges of AI is Imperative | AMCP Nexus 2024
October 22nd 2024There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
October 21st 2024Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
Read More
How Technology Benefits Specialty Pharmacy | AMCP 2024
October 18th 2024Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research, explains how technology identifies at-risk patients, coordinates medication refills and more.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
